Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01294891 · ClinicalTrials.gov registry record

Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease

A clinical trial of Sickle Cell Disease and Paroxysmal Nocturnal Hemoglobinuria, sponsored by Oregon Health and Science University.

Completed
Registry status
6
Enrollment target
1
Study location

NCT01294891: Completed study of Sickle Cell Disease and Paroxysmal Nocturnal Hemoglobinuria, sponsored by Oregon Health and Science University.

NCT01294891 is a study of Sickle Cell Disease and Paroxysmal Nocturnal Hemoglobinuria that has completed, run by Oregon Health and Science University. The registered enrollment target is 6 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01294891, a study of Sickle Cell Disease and Paroxysmal Nocturnal Hemoglobinuria, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
6 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine how abnormal blood flow in the small vessels (microvessels) of the heart, muscle and kidney in paroxysmal nocturnal hemoglobinuria (PNH) or sickle cell disease leads to poor functioning of the heart and kidney. To test this question, the investigators will perform imaging tests (contrast ultrasound perfusion imaging) to look at the flow and function of these microvessels and compare this information to heart and kidney function. To further look at this question, patients who have PNH will be studied before and after starting a new drug (Soliris) that decreases damage to blood cells. In patients with sickle cell disease, patients will be studied at baseline (not during a pain crisis) and also during a pain crisis if one develops.

Primary Outcome

1. Myocardial microvascular blood flow (MBF) and capillary blood velocity (CBV) on study day. 2. Renal MBF on study day 3. Skeletal muscle MBF and CBV on study day 4. Myocardial MBF and CBV during hyperemia 5. Skeletal muscle CBV during hyperemia

Conditions Studied

Sickle Cell Disease Paroxysmal Nocturnal Hemoglobinuria Rheologic Disease

Interventions

  • OTHER Imaging

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2011-02
Est. Completion 2014-10
Oregon Health and Science University

546 total trials

What the finished NCT01294891 record still lists

NCT01294891 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Imaging is the first listed.

NCT01294891 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT01294891 about?

NCT01294891 is a clinical study titled "Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease". The purpose of this study is to examine how abnormal blood flow in the small vessels (microvessels) of the heart, muscle and kidney in paroxysmal nocturnal hemoglobinuria (PNH) or sickle cell disease leads to poor functioning of the heart and kidney. To test this question, the investigators will per...

What is the current status of trial NCT01294891?

This trial is currently completed. The enrollment target is 6 participants. The study started on 2011-02. Estimated completion is 2014-10.

What conditions does trial NCT01294891 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Paroxysmal Nocturnal Hemoglobinuria, Rheologic Disease.

What interventions are being tested in trial NCT01294891?

The interventions under investigation include: Imaging (OTHER).

Who is sponsoring clinical trial NCT01294891?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01294891 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01294891's enrollment target sits among peer trials

6 205th of 213 higher than 7 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01294891, the US trial registry maintained by the National Library of Medicine. NCT01294891 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.